Chinese biotech Akeso Pharmaceuticals announced successful completion of Phase 3 trials for two monoclonal antibodies: gumokimab in ankylosing spondylitis and manfidokimab in moderate to severe atopic dermatitis. Both candidates met all primary efficacy endpoints, significantly advancing Akeso’s immunotherapy portfolio outside oncology and paving the way for planned regulatory submissions in the Chinese market.